Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
DSFLAT this is no place to post antivax Youtube clips from a nurse with a ropey PhD who has been found out for giving misleading information numerous times. Also, white clots are not a new disease they are well documented and have been for many years. Take your BS back to where it belongs - Youtube.
You may disagree but - director is a title given to many managers with responsibility for people (Not what it used to be - I am one and I direct nothing!)Cepheid - Revenue for 2022 - $4.3 Billion
Beckman Coulter - Revenue for 2022 - $4.7 Billion
Roache Diagnostics Division - Revenue for 2022 - $17.7 Billion
All blue chip companies with established brand and huge installed base - completely different to commercialising a new technology into global healthcare systems.
JC is a nice guy - an excellent contracts manager but do I believe he will achieve what he set out to (and Budd before him who was also ex Siemens / Leica etc) No I don't. I believe my gamble to invest has gone the wrong way and without a big pharma acquisition this will go nowhere. Nothing will make me happier to be proved wrong as I could recoup some of my losses!
I don't think a lot of posters do any real research on JC. He was a company guy in a middle manager position - no BOD experience and certainly not managed to get a start up firing on all cylinders. great at contract management but not so much at getting contracts / Q&RA / Sales / M&A etc.
I, like many hear am underwater with this dog share but I don't share the unqualified optimism that some do. Hope is not a strategy but it is all we have!
Do the words "under a penny" not make you shudder when you see where it started?? This is a dog share - recovery for many people just will not happen. If you started at under a penny they fair play - it could double to 2p but sell when it does!!!!!
Cheek has zero experience with start ups. I know he has worked with Beckman Coulter and Roche but they are huge multinationals with a vast marketing machine behind them. Mr Cheek is a highly experienced contracts manager - don't expect too much.
Mr Budd was similar - Bayer / Siemens regional sales manager and look where he has got us to.....
This technology is very cool but unless a big player gets behind it I cant see it going anywhere - it is why so many cool biotechs fail. I hope I am wrong.
You keep telling yourself that Starres. These events are great opportunities for pen collectors. I know because I have the misery of attending them regularly and have done so for many years.
POCT coordinators are also incredibly proficient at blocking new technology even when a clinician embraces it. I agree it is useful to have their name out there but nothing commercial will come of exhibiting at this event.
Seems to be making steady growth - I prefer it this way and hope I have not inflicted a savage blow!
As previously stated the RNS is what will make the difference but trading looks much better and my half full side is feeling positive for a slow climb back to sensible levels.
Thanks Alamo. Been invested in this for >2 years so not looking for an overnight profit nor am I complaining about its performance - AIM shares are risky. I was saying these stupid comments - Hold for gold etc, etc are just ridiculous. AIHL looks interesting and has a market but getting it taken up is incredibly complex and will be a slow process. I work in the POCT market and have experienced bringing amazing tests to market - they don't just start ordering (Unfortunately!)